Renal Care News
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
-
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
By Bayer AG
-
INCOGEN Completes NIH Funded BISTI Project
INCOGEN and its collaborators announced the completion of the five-year long clear cell renal cell carcinoma (ccRCC) project. This multidisciplinary project was funded by several National Cancer Institute Small Business Innovation Research (SBIR) grants and involved collaborations with the Mayo Clinic, Eastern Virginia Medical School, and Johns Hopkins University. It resulted in the development ...
-
Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes
Creative Enzymes, a global leader in diagnostic enzyme manufacturing and supply, is dedicated to offering a wide range of enzyme products as well as customized enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched kidney and pancreas function diagnostic enzymes for the global market. The primary function of the kidney is to eliminate waste and excess ...
-
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
By Bayer AG
-
Bodyport Announces Appointment of Jim Pursley to Board of Directors
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. “I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to ...
-
Apollo Medical Holdings, Inc. Receives NCQA`s HEDIS Health Plan Measure Certification for Measurement Year 2022
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") for ...
-
Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function ...
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
-
Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by baseline HbA1c, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) An exploratory ...
By Bayer AG
-
BlueWind Medical Ltd. Makes Key Additions to Leadership Team
BlueWind Medical, in preparation for commercialization of the RENOVA product line, announces the hiring of key positions within the organization. Vice President of Sales Mike Ruger, Vice President of Marketing Sandra Muhlfeld, and Vice President of Human Resources Lisa Mead. BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment ...
-
Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention ...
-
GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
-
Bodyport Receives FDA Clearance for the Bodyport Cardiac Scale
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. This innovative solution enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess ...
-
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today it has entered into a Royalty Interest Purchase and Sale Agreement (the agreement) with HealthCare Royalty Partners (HealthCare Royalty). Clearside intends to use the proceeds from the agreement to ...
-
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...
-
Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart
Montreal-based Puzzle Medical Devices Inc., announced today the successful completion of the company’s ?rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). Four patients had ModulHeart deployed to provide circulatory support while undergoing ...
-
Procyrion Selects Former Abbott/St. Jude Medical Group President Dr. Eric S. Fain as CEO
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, has named Eric S. Fain, MD as President and Chief Executive Officer effective immediately. The Board of Directors tapped Dr. Fain to build upon the foundation of innovative technology established over recent years and accelerate the progression of product development ...
-
Bodyport Appoints John Lipman as Chief Executive Officer
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company. Lipman’s appointment comes as Bodyport prepares for ...
-
Angiodroid turns 500!
The number 500 is associated, for Italian culture, with a famous car that has marked the history of evolution and progress. We are particularly attached to this number, today more than ever. In 2021, Angiodroid exceeded 500 injectors on the market, opening up to a new age: despite the difficult times given by the Covid-19 pandemic, Angiodroid reached this milestone, which marks a new beginning ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you